Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib

REFERENCES

• Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992; 267: 10931–10934
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med. 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Lichtenbeld H. H.C., van Dam-Mieras M. C.E., Hillen H.F.P. Tumor angiogenesis: pathophysiology and clinical significance. The Netherlands Journal of Medicine 1996; 49: 42–51
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. Journal of Med. 2004; 3(23)350, 2406–2408
   Google Scholar
• Lyseng-Williamson K. A., Robinson D. M. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 2006; 20(3)193–195
   PubMed Web of Science ®Google Scholar
• Yang J. C., Haworth L., Sherry R. M., Hwu, Schwartzentruber D. J., Topalina S. L., Steinberg S. M., Chen H. X., Rosenberg S. A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. Journal of Med. 2003 Jul 31; 349(5)27–34
   PubMedGoogle Scholar
• Motzer R. J., Hutson T. E., Tomczak P., et al. Figlin Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings Part I. 2006; LBA3, Vol 24, No. 18S (June 20 Supplement)
   Google Scholar
• Browder T., Butterfield C. E., Kraling B. M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–1886
   PubMed Web of Science ®Google Scholar
• Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D. J., Bohle Kerbel R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin. Invest. 2000; 105: R15–24
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J. A. Oral alkylating agents for breast cancer. Drugs 1999; 58(Suppl 3)1–9
   PubMed Web of Science ®Google Scholar
• Rocca A., Colleoni M., Nole F., et al. Lowdose oral Methotrexate (MTX) and Cyclophosphamide (CTX) in Metastatic Breast cancer (MBC): Antitumor Activity and Correlation with Serum Vascular Endothelial Growth Factor (VEGF) levels. Proceedings of American Society of Clinical Oncology 1999, Abstract #460
   Google Scholar
• Masferrer J. L., Koki A., Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann. N. Y. Acad. Sci. 1999; 889: 84–86
   PubMed Web of Science ®Google Scholar
• Weidner N. Tumour vascularity and proliferation: clear evidence of a close relationship. J. Pathol. 1999 Nov; 189(3)309–318
   PubMedGoogle Scholar
• Weidner N. Angiogenesis as a predictor of clinical outcome ion cancer patients. Hum. Pathol 2000; 31: 403–405
   PubMed Web of Science ®Google Scholar
• Hylton M. J Clin Oncol Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. 2006 Jul 10; 24(20)3293–3298
   Google Scholar
• Bremnes R. M., Camps C., Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung cancer 2006 Feb; 51(2)143–158
   PubMed Web of Science ®Google Scholar
• Mancuso P., Burlini A., Pruneri G., et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658–3661
   PubMed Web of Science ®Google Scholar
• Andrew D., Blann Alexander Woywodt, Bertolini Francesco, Todd M. Bull, Jill P, Buyonm Robert M. Clancy, Haubitz Marion, Robert P. Hebbel, Gregory Y, Lip H., Mancuso Patrizia, Sampol Jose, Solovey Anna, Dignat-George Francoise. Circulating endothelial cells. Thrombosis Haemost 2005; 93: 228–235
   PubMed Web of Science ®Google Scholar
• Lyden D., et al. Impaired recruitment of bone marrow-derived endothelial and hematopoetic precursor cells blocks tumor angiogenesis ands growth. Nature Med. 2001; 7: 1194–1201
   PubMed Web of Science ®Google Scholar
• Del Papa N., Colombo G., Fracchiolla N., et al. Circulating endothelial as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004; 50: 1296–1304
   PubMed Web of Science ®Google Scholar
• Woywodt A., Goldberg C., Scheer J., et al. A novel assay for the enumeration of circulating endothelial cells. Annals Hematol 2004; 83: 491–494
   PubMed Web of Science ®Google Scholar
• Goon P. K., Lip G. Y., Boos C. J., Stonelake P. S., Blann A. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79–88
   PubMed Web of Science ®Google Scholar
• Solovey A. N., et al. Identification and functional assessment of endothelial P1H12. J. Lab. Clin. Med. 2001; 5: 322–331
   Google Scholar